• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRAF V600E 与朗格汉斯细胞组织细胞增生症成人中第二癌症的更高发生率相关。

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.

机构信息

Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Division of Hematology, Mayo Clinic, Rochester, MN.

出版信息

Blood. 2023 Nov 2;142(18):1570-1575. doi: 10.1182/blood.2023021212.

DOI:10.1182/blood.2023021212
PMID:37595284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10797504/
Abstract

In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.

摘要

在这项回顾性研究中，BRAF 突变状态与 156 例朗格汉斯细胞组织细胞增生症成人患者的疾病范围或（无事件）生存无关。BRAFV600E 与第二恶性肿瘤的发生率增加相关，这些肿瘤通常包括血液系统癌症，可能与克隆相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0960/10797504/4689e2eb8d74/BLOOD_BLD-2023-021212-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0960/10797504/4689e2eb8d74/BLOOD_BLD-2023-021212-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0960/10797504/4689e2eb8d74/BLOOD_BLD-2023-021212-ga1.jpg

相似文献

1
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.BRAF V600E 与朗格汉斯细胞组织细胞增生症成人中第二癌症的更高发生率相关。
Blood. 2023 Nov 2;142(18):1570-1575. doi: 10.1182/blood.2023021212.
2
BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.BRAF V600E 和 Pten 缺失在小鼠中产生具有朗格汉斯细胞组织细胞增生症特征的组织细胞疾病。
PLoS One. 2019 Sep 17;14(9):e0222400. doi: 10.1371/journal.pone.0222400. eCollection 2019.
3
BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH.诊断时血液中BRAF V600E阳性单核细胞预示着儿童朗格汉斯细胞组织细胞增多症的治疗失败和神经变性。
Blood. 2025 Jul 10;146(2):206-218. doi: 10.1182/blood.2024026671.
4
Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations.解析韩国患者朗格汉斯细胞组织细胞增多症的遗传图谱：来自突变谱和临床相关性的全面见解
Cancer Res Treat. 2025 Jul;57(3):873-882. doi: 10.4143/crt.2024.782. Epub 2024 Dec 24.
5
Efficacy of BRAF-Inhibitor Therapy in BRAF -Mutated Adult Langerhans Cell Histiocytosis.BRAF抑制剂疗法对BRAF突变型成人朗格汉斯细胞组织细胞增多症的疗效
Oncologist. 2020 Dec;25(12):1001-1004. doi: 10.1002/onco.13541. Epub 2020 Oct 12.
6
High prevalence of BRAF in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis.高患病率的 BRAF 在胆淤积症患者中，硬皮胆管炎或纤维化的肝脏继发于朗格汉斯细胞组织细胞增生症。
Pediatr Blood Cancer. 2021 Jul;68(7):e29115. doi: 10.1002/pbc.29115. Epub 2021 May 15.
7
Prevalence of the mutation in Greek adults with Langerhans cell histiocytosis.希腊成年人朗格汉斯组织细胞增生症中 突变的流行率。
Pediatr Hematol Oncol. 2022 Sep;39(6):540-548. doi: 10.1080/08880018.2022.2029988. Epub 2022 Feb 10.
8
Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.儿童 MAP2K1 突变朗格汉斯细胞组织细胞增生症的临床研究。
J Cancer Res Clin Oncol. 2022 Sep;148(9):2517-2527. doi: 10.1007/s00432-021-03810-4. Epub 2021 Sep 30.
9
Assessment of BRAF mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction.通过液滴数字聚合酶链反应评估组织活检和支气管肺泡灌洗中肺朗格汉斯细胞组织细胞增生症的BRAF突变
Virchows Arch. 2018 Feb;472(2):247-258. doi: 10.1007/s00428-017-2185-0. Epub 2017 Jul 15.
10
[BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].[BRAF-V600E突变及其在朗格汉斯细胞组织细胞增多症患儿中的临床意义]
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):290-294. doi: 10.7499/j.issn.1008-8830.2018.04.007.

引用本文的文献

1
Pulmonary Langerhans cell histiocytosis: A case series and literature review.肺朗格汉斯细胞组织细胞增多症：病例系列及文献综述
J Clin Imaging Sci. 2025 Jun 10;15:21. doi: 10.25259/JCIS_42_2025. eCollection 2025.
2
Eruptive widespread crateriform papulonodules and back pain: An interesting case of Langerhans cell histiocytosis?爆发性广泛的火山口状丘疹结节与背痛：朗格汉斯细胞组织细胞增多症的一个有趣病例？
JAAD Case Rep. 2025 Apr 17;60:132-134. doi: 10.1016/j.jdcr.2025.03.032. eCollection 2025 Jun.
3
NTRK1-rearranged histiocytosis: clinicopathologic and molecular features.

本文引用的文献

1
BRAF testing modalities in histiocytic disorders: Comparative analysis and proposed testing algorithm.组织细胞疾病中 BRAF 检测方法：比较分析与检测方法建议
Am J Clin Pathol. 2023 Nov 2;160(5):483-489. doi: 10.1093/ajcp/aqad076.
2
Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis.儿童及成人朗格汉斯细胞组织细胞增多症的第二原发性恶性肿瘤谱及特定病因死亡率
Leuk Res. 2023 Mar;126:107032. doi: 10.1016/j.leukres.2023.107032. Epub 2023 Feb 6.
3
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
NTRK1重排组织细胞增多症：临床病理及分子特征
Blood Adv. 2025 Jul 22;9(14):3617-3628. doi: 10.1182/bloodadvances.2025016167.
4
Risk of Second Cancer in Erdheim-Chester Disease.厄德里希-切斯特病的二次癌症风险
JAMA Oncol. 2025 Feb 27;11(4):429-33. doi: 10.1001/jamaoncol.2025.0011.
5
IDCH: is it now determined?国际疾病分类临床修订本：现在确定了吗？
Blood Adv. 2025 Feb 11;9(3):496-498. doi: 10.1182/bloodadvances.2024014843.
6
Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.非典型性树突状细胞组织细胞增多症中的复发性ETV3::NCOA2融合和MAPK通路突变
Blood Adv. 2025 Feb 11;9(3):439-444. doi: 10.1182/bloodadvances.2024013696.
7
Comprehensive considerations for dermatologists: the application of FDG-PET in evaluating cutaneous lesions in pediatric Langerhans cell histiocytosis.皮肤科医生的综合考量：FDG-PET在评估儿童朗格汉斯细胞组织细胞增多症皮肤病变中的应用
Front Med (Lausanne). 2024 Jul 10;11:1378638. doi: 10.3389/fmed.2024.1378638. eCollection 2024.
8
Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.伴 FLT3-ITD 和 PTPN11 突变的克隆性演变急性髓系白血病与 Erdheim-Chester 病共存。
Ann Hematol. 2024 Aug;103(8):3229-3233. doi: 10.1007/s00277-024-05842-5. Epub 2024 Jun 15.
9
Langerhans cell histiocytosis of the suprasellar region: diagnosis based on thyroid cytology.鞍上区朗格汉斯细胞组织细胞增生症：基于甲状腺细胞学的诊断。
Eur Thyroid J. 2024 May 30;13(3). doi: 10.1530/ETJ-24-0011. Print 2024 Jun 1.
10
[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].[非小细胞肺癌中BRAF基因改变的研究进展]
Zhongguo Fei Ai Za Zhi. 2024 Jan 20;27(1):73-80. doi: 10.3779/j.issn.1009-3419.2024.101.01.
儿童朗格汉斯细胞组织细胞增生症的临床基因组关联：一项国际队列研究。
Blood Adv. 2023 Feb 28;7(4):664-679. doi: 10.1182/bloodadvances.2022007947.
4
Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients.朗格汉斯细胞组织细胞增生症及相关恶性肿瘤：270 例回顾性分析。
Eur J Cancer. 2022 Sep;172:138-145. doi: 10.1016/j.ejca.2022.03.036. Epub 2022 Jun 27.
5
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders.BRAF融合在组织细胞疾病中的临床及治疗意义
Blood Cancer J. 2022 Jun 28;12(6):97. doi: 10.1038/s41408-022-00693-7.
6
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.国际专家共识建议：成人朗格汉斯细胞组织细胞增生症的诊断与治疗。
Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343.
7
Prevalence of the mutation in Greek adults with Langerhans cell histiocytosis.希腊成年人朗格汉斯组织细胞增生症中 突变的流行率。
Pediatr Hematol Oncol. 2022 Sep;39(6):540-548. doi: 10.1080/08880018.2022.2029988. Epub 2022 Feb 10.
8
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.成人朗格汉斯细胞组织细胞增生症患者的治疗结果和预后因素。
Am J Hematol. 2022 Feb 1;97(2):203-208. doi: 10.1002/ajh.26412. Epub 2021 Nov 23.
9
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.伴有相同致癌突变的不同血液系统恶性肿瘤相关组织细胞肿瘤谱。
J Pathol Clin Res. 2021 Jan;7(1):10-26. doi: 10.1002/cjp2.177. Epub 2020 Aug 27.
10
Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.骨髓源性髓系前体细胞作为高风险和低危朗格汉斯细胞组织细胞增生症的驱动突变携带者。
Blood. 2020 Nov 5;136(19):2188-2199. doi: 10.1182/blood.2020005209.